Patient outcomes
| Outcome . | Study population (n = 20) . |
|---|---|
| Response at 1 mo | |
| Complete response | 12 (60%) |
| Partial response | 3 (15%) |
| Stable disease | 3 (15%) |
| Progressive disease | 1 (5%) |
| Unknown | 1 (5%) |
| Best response | |
| Complete response | 15 (75%) |
| Partial response | 1 (5%) |
| Stable disease | 1 (5%) |
| Progressive disease | 3 (15%) |
| Acute GVHD | 17 (85%) |
| Chronic GVHD | 9 (45%) |
| PFS, median, y | 1.57 (95 CI, 0.22-6.94) |
| OS, median, y | 6.45 (1.10 lower limit; upper limit does not exist) |
| Outcome . | Study population (n = 20) . |
|---|---|
| Response at 1 mo | |
| Complete response | 12 (60%) |
| Partial response | 3 (15%) |
| Stable disease | 3 (15%) |
| Progressive disease | 1 (5%) |
| Unknown | 1 (5%) |
| Best response | |
| Complete response | 15 (75%) |
| Partial response | 1 (5%) |
| Stable disease | 1 (5%) |
| Progressive disease | 3 (15%) |
| Acute GVHD | 17 (85%) |
| Chronic GVHD | 9 (45%) |
| PFS, median, y | 1.57 (95 CI, 0.22-6.94) |
| OS, median, y | 6.45 (1.10 lower limit; upper limit does not exist) |